966 related articles for article (PubMed ID: 21969420)
1. Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia.
Grant PM; Huh GA; Perivoliotis D; Stolar NM; Beck AT
Arch Gen Psychiatry; 2012 Feb; 69(2):121-7. PubMed ID: 21969420
[TBL] [Abstract][Full Text] [Related]
2. Sustained and "sleeper" effects of group metacognitive training for schizophrenia: a randomized clinical trial.
Moritz S; Veckenstedt R; Andreou C; Bohn F; Hottenrott B; Leighton L; Köther U; Woodward TS; Treszl A; Menon M; Schneider BC; Pfueller U; Roesch-Ely D
JAMA Psychiatry; 2014 Oct; 71(10):1103-11. PubMed ID: 25103718
[TBL] [Abstract][Full Text] [Related]
3. Cognitive enhancement therapy for schizophrenia: effects of a 2-year randomized trial on cognition and behavior.
Hogarty GE; Flesher S; Ulrich R; Carter M; Greenwald D; Pogue-Geile M; Kechavan M; Cooley S; DiBarry AL; Garrett A; Parepally H; Zoretich R
Arch Gen Psychiatry; 2004 Sep; 61(9):866-76. PubMed ID: 15351765
[TBL] [Abstract][Full Text] [Related]
4. A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.
Weiser M; Heresco-Levy U; Davidson M; Javitt DC; Werbeloff N; Gershon AA; Abramovich Y; Amital D; Doron A; Konas S; Levkovitz Y; Liba D; Teitelbaum A; Mashiach M; Zimmerman Y
J Clin Psychiatry; 2012 Jun; 73(6):e728-34. PubMed ID: 22795211
[TBL] [Abstract][Full Text] [Related]
5. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
[TBL] [Abstract][Full Text] [Related]
6. Cognitive therapy for people with a schizophrenia spectrum diagnosis not taking antipsychotic medication: an exploratory trial.
Morrison AP; Hutton P; Wardle M; Spencer H; Barratt S; Brabban A; Callcott P; Christodoulides T; Dudley R; French P; Lumley V; Tai SJ; Turkington D
Psychol Med; 2012 May; 42(5):1049-56. PubMed ID: 21914252
[TBL] [Abstract][Full Text] [Related]
7. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE
JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
[TBL] [Abstract][Full Text] [Related]
8. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
Nakamura M; Ogasa M; Guarino J; Phillips D; Severs J; Cucchiaro J; Loebel A
J Clin Psychiatry; 2009 Jun; 70(6):829-36. PubMed ID: 19497249
[TBL] [Abstract][Full Text] [Related]
9. Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: a randomized, double-blind, proof-of-concept study.
Umbricht D; Alberati D; Martin-Facklam M; Borroni E; Youssef EA; Ostland M; Wallace TL; Knoflach F; Dorflinger E; Wettstein JG; Bausch A; Garibaldi G; Santarelli L
JAMA Psychiatry; 2014 Jun; 71(6):637-46. PubMed ID: 24696094
[TBL] [Abstract][Full Text] [Related]
10. An RCT of adherence therapy for people with schizophrenia in Chiang Mai, Thailand.
Maneesakorn S; Robson D; Gournay K; Gray R
J Clin Nurs; 2007 Jul; 16(7):1302-12. PubMed ID: 17584349
[TBL] [Abstract][Full Text] [Related]
11. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
[TBL] [Abstract][Full Text] [Related]
12. The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial.
Schoemaker JH; Jansen WT; Schipper J; Szegedi A
J Clin Psychopharmacol; 2014 Apr; 34(2):190-8. PubMed ID: 24525661
[TBL] [Abstract][Full Text] [Related]
13. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
[TBL] [Abstract][Full Text] [Related]
14. Clinical effectiveness of individual cognitive behavioral therapy for depressed older people in primary care: a randomized controlled trial.
Serfaty MA; Haworth D; Blanchard M; Buszewicz M; Murad S; King M
Arch Gen Psychiatry; 2009 Dec; 66(12):1332-40. PubMed ID: 19996038
[TBL] [Abstract][Full Text] [Related]
15. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
[TBL] [Abstract][Full Text] [Related]
16. Cognitive-behavioural therapy for patients with schizophrenia: a multicentre randomized controlled trial in Beijing, China.
Li ZJ; Guo ZH; Wang N; Xu ZY; Qu Y; Wang XQ; Sun J; Yan LQ; Ng RM; Turkington D; Kingdon D
Psychol Med; 2015 Jul; 45(9):1893-905. PubMed ID: 25532460
[TBL] [Abstract][Full Text] [Related]
17. Neurocognitive effects of ziprasidone and related factors in patients with chronic schizophrenia undergoing usual care: a 12-month, open-label, flexible-dose, naturalistic observational trial.
Gibel A; Ritsner MS
Clin Neuropharmacol; 2008; 31(4):204-20. PubMed ID: 18670244
[TBL] [Abstract][Full Text] [Related]
18. Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.
Geffen Y; Keefe R; Rabinowitz J; Anand R; Davidson M
J Clin Psychiatry; 2012 Sep; 73(9):e1168-74. PubMed ID: 23059159
[TBL] [Abstract][Full Text] [Related]
19. Effects of tapering of long-term benzodiazepines on cognitive function in patients with schizophrenia receiving a second-generation antipsychotic.
Kitajima R; Miyamoto S; Tenjin T; Ojima K; Ogino S; Miyake N; Fujiwara K; Funamoto Y; Arai J; Tsukahara S; Ito Y; Tadokoro M; Anai K; Kaneda Y; Yamaguchi N
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):300-6. PubMed ID: 22122880
[TBL] [Abstract][Full Text] [Related]
20. Antipsychotic treatment beyond antipsychotics: metacognitive intervention for schizophrenia patients improves delusional symptoms.
Moritz S; Veckenstedt R; Randjbar S; Vitzthum F; Woodward TS
Psychol Med; 2011 Sep; 41(9):1823-32. PubMed ID: 21275083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
